// App-Quantinova.ai

: Cabozantinib plus androgen deprivation therapy in patients with androgen-dependent metastatic prostate cancer.

Researchers

Presenter

  • Paul Gettys Corn

Principal Investigators

  • Amado J. Zurita

  • Sumit Kumar Subudhi

  • Shi-Ming Tu

  • Ana Aparicio

  • John C. Araujo

  • Jeri Kim

  • Jennifer Wang

  • Eleni Efstathiou

  • Lance C. Pagliaro

  • Christopher Logothetis

Medical Centers

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Alexandra General Hospital of Athens, University of Athens, Athens, Greece

  • Mayo Clinic, Rochester, MN

Locations

  • United States

  • Greece

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Cabozantinib

  • Androgen Tear

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT01630590

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved